AudiologyOnline Phone: 800-753-2160


MED-EL SYNCHRONY- December 2019

What Speech Perception Outcomes Were Observed in a Clinical Trial of the MED-EL EAS Cochlear Implant System?

Allison Racey, AuD

August 28, 2017

Share:

Question

Can you provide an overview of the clinical trial for the MED-EL Electric-Acoustic Stimulation (EAS) Cochlear Implant System that demonstrated significant improvements in performance with EAS compared to pre-operative results with hearing aids?

Answer

FDA approval for the MED-EL Electric-Acoustic Stimulation (EAS) Cochlear Implant System was recently granted by the FDA based on MED-EL’s results from a clinical trial with 73 participants from 14 investigative sites across the United States. The purpose of the clinical trial was to demonstrate that the EAS System would be safe and effective to use in individuals meeting the defined candidacy criteria (residual low-frequency hearing with severe to profound hearing loss in the high frequencies and speech understanding scores of 60% or less on words in quiet). Of the 73 participants who were enrolled in the clinical trial and implanted with the EAS device, 67 participants were followed through 12 months post-operatively. These 67 individuals were tested on speech understanding measures both in quiet (Consonant-Nucleus-Consonant, CNC words) and in noise (City University of New York, CUNY sentences). Participants also completed questionnaires assessing self-perceived benefit and satisfaction with the EAS device.

MED-EL Electric-Acoustic Stimulation Cochlear Implant System

At 12 months post-operatively, scores on CNC words improved on average 37 percentage points, from 30% correct at the pre-operative interval to 67% correct at 12 months post-operatively with EAS. For CUNY sentences in noise, scores improved on average 42 percentage points, from 31% correct at the pre-operative interval to 73% correct at 12 months post-operatively with EAS. In the EAS condition, 97% of the 67 participants completing testing at 12 months performed similarly to or better than their preoperative performance on CNC words in quiet, while 94% performed similarly to or better than their pre-operative score on CUNY sentences in noise.

Participants also demonstrated improvements in speech understanding when tested with electric stimulation only. In this condition, individuals demonstrated an 18 percentage point improvement on average for CNC words in quiet, and a 25 percentage point improvement for CUNY sentences in noise. These results demonstrate that even in a worst-case scenario in which a patient loses low-frequency residual hearing, performance with electric stimulation only is improved compared to pre-operative hearing aid performance.

Individuals in the clinical trial also completed two subjective questionnaires: the Abbreviated Profile of Hearing Aid Benefit (APHAB) and Hearing Device Satisfaction Scale (HDSS). On the APHAB, participants demonstrated an average improvement in ease of listening of 30 percentage points. Of the individuals completing the questionnaire at 12 months, 90% demonstrated an improvement with EAS compared to their pre-operative hearing aids. Specifically, in terms of ease of listening in background noise, 92% of participants at 12 months reported an improvement with EAS compared to pre-operative hearing aids. Based on results from the HDSS questionnaire, 86% of participants indicated an improvement in device satisfaction with EAS compared to pre-operative hearing aids.

Overall, these results demonstrate significant improvements in performance with EAS compared to pre-operative results with hearing aids. Individuals in the clinical trial showed benefit with EAS on speech understanding in quiet and in noise, as well as on subjective questionnaires. Overall, 99% of participants demonstrated benefit on at least one performance outcome measure. The results from this clinical trial represent a large pool of individuals from which to conclude that EAS is effective for use in patients with residual low-frequency hearing and severe to profound high-frequency sensorineural hearing loss.

For more information on the MED-EL EAS Cochlear Implant System, visit http://www.medel.com/us/ or the MED-EL Expo on AudiologyOnline.


allison racey

Allison Racey, AuD

Manager of Regulated Research

Allison Racey, AuD is the Manager of Regulated Research at MED-EL Corporation. She manages FDA-regulated studies, including multi-center clinical trials, in which MED-EL is involved. As part of managing these studies, she provides training and support to investigators involved in these projects. Additionally, she interacts with the FDA as needed on regulated-research issues. Allison received her Doctorate in Audiology from the University of North Carolina at Chapel Hill in 2009. She spent time working in private practice prior to joining MED-EL Corporation in 2011. Bringing hearing implant technology to those who have exhausted other, non-surgical options is a top priority for Allison.


Related Courses

MED-EL Electric-Acoustic Stimulation Clinical Trial Outcomes
Presented by Allison Racey, AuD, Meg Dillon, AuD
Recorded Webinar
MED-EL

Presenters

Allison Racey, AuDMeg Dillon, AuD
Course: #28485Level: Intermediate1 Hour
  'The way the research was explained and compared to similar devices'   Read Reviews
In this course presenters will discuss the study design and important outcomes from the US Clinical Trial for Electric-Acoustic Stimulation. Data collected from study subjects will be presented within the context of the clinical trial as well as from additional testing completed at the lead study site.

View this Course for FREE.
Need CEUs? Become a AudiologyOnline member to get unlimited CEUs.

Only $99/yr

Learn More

Introducing MED-EL Cochlear Implants for Persons with Single-Sided Deafness (SSD) and Asymmetric Hearing Loss (AHL)
Presented by Allison Racey, AuD, Meg Dillon, AuD
Recorded Webinar
MED-EL

Presenters

Allison Racey, AuDMeg Dillon, AuD
Course: #33949Level: Introductory1 Hour
  'I enjoyed learning the details of the study'   Read Reviews
The FDA has recently approved Single-Sided deafness (SSD) and Asymmetric Hearing Loss (AHL) as a new indication for MED-EL cochlear implants. This course will review data collected by one of the study sites used for this approval as well as Quality of Life data collected in these populations.

View this Course for FREE.
Need CEUs? Become a AudiologyOnline member to get unlimited CEUs.

Only $99/yr

Learn More

Mi Casa, Tu Casa (En Casa!)
Presented by Laura Corcoran
Recorded Webinar
MED-EL

Presenter

Laura Corcoran
Course: #36129Level: Introductory1 Hour
  'material was presented in an orderly professional manner'   Read Reviews
Latinos are the fastest growing minority in the U.S. and it’s estimated that 1 in 7 Latinos have a hearing loss. This webinar will introduce MED-EL’s Bilingual Program, a unique cultural approach to serving and supporting this community.

View this Course for FREE.
Need CEUs? Become a AudiologyOnline member to get unlimited CEUs.

Only $99/yr

Learn More

Auditory Practice for Electric Acoustic Stimulation (EAS) Recipients
Presented by MaryKay Therres
Recorded Webinar
MED-EL

Presenter

MaryKay Therres
Course: #28733Level: Intermediate1 Hour
  'Good explanations of the topic, easy to follow and understand'   Read Reviews
This presentation will provide a general review of candidacy for Electric Acoustic Stimulation (EAS) and impact of mid to high frequency hearing loss. It will then address specific auditory training exercises that EAS recipients can practice to adjust to new sounds and maximally benefit from their device.

View this Course for FREE.
Need CEUs? Become a AudiologyOnline member to get unlimited CEUs.

Only $99/yr

Learn More

Rehabilitation in the Single-Sided Deaf (SSD) Population
Presented by Maegan Evans, PhD, CCC-SLP, LSLS Cert. AVEd, Taylor Sands, MS, CCC-SLP, LSLS Cert. AVEd
Audio
MED-EL

Presenters

Maegan Evans, PhD, CCC-SLP, LSLS Cert. AVEdTaylor Sands, MS, CCC-SLP, LSLS Cert. AVEd
Course: #35651Level: Introductory0.5 Hours
  'It's an exploding area of our field and good to keep up with where it is going'   Read Reviews
The FDA has approved MED-EL Cochlear implants for children (aged 5 years and older) and adults with Single-Sided Deafness (SSD) or Asymmetric Hearing Loss (AHL). Maegan Evans, Ph.D., CCC-SLP, LSLS Cert. AVEd will discuss her experience developing a protocol for habilitation therapy in this unique population.

View this Course for FREE.
Need CEUs? Become a AudiologyOnline member to get unlimited CEUs.

Only $99/yr

Learn More